Clinical Trials

80 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04388852 2026-05-20

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

65 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Prostatic Neoplasms

NCT04141644 2026-05-19

Osi+Ipi

24 enrolled

Thoracic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

NCT04003649 2026-05-14

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

20 enrolled

CNS

Glioblastoma

NCT04042753 2026-05-14

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

9 enrolled

Endocrine

Pituitary Diseases, Pituitary Neoplasms

NCT06946797 2026-05-14

CheckMate-1533

Phase 2/3 Active not recruiting

76 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02339571 2026-05-13

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

600 enrolled

Melanoma

NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

152 enrolled

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT02834013 2026-05-13

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

818 enrolled

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03502733 2026-05-13

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

64 enrolled

Lymphoid

Lymphoma, Neoplasm Metastasis

NCT03604978 2026-05-13

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

38 enrolled

CNS

Meningioma

NCT03793166 2026-05-13

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

1,175 enrolled

Carcinoma, Renal Cell, Lymphatic Metastasis

NCT03816358 2026-05-13

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

74 enrolled

Pancreatic Neoplasms

NCT04317105 2026-05-13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

54 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT02314169 2026-05-12

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

143 enrolled 16 charts

Anal Canal Carcinoma, Anus Neoplasms

NCT03122522 2026-05-06

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

70 enrolled

Melanoma

NCT01274338 2026-05-05

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

1,673 enrolled 19 charts

Melanoma

NCT05012254 2026-05-05

NIVIPI-Brain

71 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT02506153 2026-05-04

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

1,301 enrolled 16 charts

Melanoma

NCT04145115 2026-05-04

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

37 enrolled

CNS

Astrocytoma, Glioblastoma

NCT05933265 2026-05-04

Study of LP-184 in Patients With Advanced Solid Tumors

64 enrolled

Breast

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT04751370 2026-05-01

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

31 enrolled

Rectal Neoplasms

NCT01708941 2026-04-30

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

88 enrolled 14 charts

Melanoma

NCT03816332 2026-04-30

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

12 enrolled 13 charts

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT02879695 2026-04-29

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

28 enrolled 16 charts

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT02890329 2026-04-29

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

MyeloidOther hematologic neoplasm

54 enrolled 15 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01134614 2026-04-28

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

245 enrolled 8 charts

Melanoma

NCT03789110 2026-04-28

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

30 enrolled 15 charts

Breast

Breast Neoplasms

NCT02812524 2026-04-24

Ipilimumab for Head and Neck Cancer Patients

18 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04080804 2026-04-22

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

80 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05836571 2026-04-21

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

66 enrolled

Sarcoma

Sarcoma, Histiocytoma, Malignant Fibrous

NCT03776487 2026-04-15

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

32 enrolled

Clinical Stage 0 Gastric Cancer AJCC v8

NCT06049576 2026-04-15

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

31 enrolled

Carcinoma, Renal Cell

NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

BreastOther solid neoplasm

57 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT03650894 2026-04-13

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

30 enrolled

Breast

Breast Neoplasms

NCT03914300 2026-04-13

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

11 enrolled 11 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT04079712 2026-04-13

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

17 enrolled 12 charts

EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT05407441 2026-04-13

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

49 enrolled

Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT05289193 2026-04-07

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

28 enrolled

Melanoma

NCT04039607 2026-04-06

CheckMate 9DW

732 enrolled 1 FDA

Carcinoma, Hepatocellular

NCT04709276 2026-04-06

CHAMP

41 enrolled

Prostatic Neoplasms

NCT03355976 2026-04-02

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

46 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT03377023 2026-04-02

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

66 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer